Clearmind Medicine (CMND) Enterprise Value (2021 - 2026)
Clearmind Medicine (CMND) posted quarterly Enterprise Value of -$13.6 million for Q2 2026, down 192.32% year-over-year from $14.7 million in Q2 2025, and down 31.37% quarter-over-quarter from -$10.3 million in Q1 2026.
Clearmind Medicine (CMND) Enterprise Value (2021 - 2026) Analysis & Trends
Clearmind Medicine's Enterprise Value history runs 6 years deep, the most recent figure standing at -$13.6 million for Q2 2026.
- In Q2 2026, Enterprise Value fell 192.32% year-over-year to -$13.6 million; the TTM figure through Apr 2026 stood at -$13.6 million (down 192.32% YoY), while the FY2025 annual figure was -$5.6 million, up 18.62% from the prior year.
- Enterprise Value for Q2 2026 stood at -$13.6 million, down from -$10.3 million in the prior quarter.
- The five-year high for Enterprise Value was -$147392.8 in Q4 2022, with the low at -$13.6 million in Q2 2026.
- The 5-year median for Enterprise Value is -$5.6 million (2025), against an average of -$6.1 million.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value surged 95.99% in 2022, then plunged 3640.92% in 2023.
- Clearmind Medicine's Enterprise Value stood at -$147392.8 in 2022, then slumped by 3640.92% to -$5.5 million in 2023, then dropped by 24.47% to -$6.9 million in 2024, then gained by 18.62% to -$5.6 million in 2025, then tumbled by 143.37% to -$13.6 million in 2026.
- Business Quant data shows CMND's Enterprise Value at -$13.6 million in Q2 2026, -$10.3 million in Q1 2026, and -$5.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - | -13.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -13.59 Mn |
| Jan 31, 2026 | -10.35 Mn |
| Oct 31, 2025 | -5.59 Mn |
| Jul 31, 2025 | -3.50 Mn |
| Apr 30, 2025 | -4.65 Mn |
| Jan 31, 2025 | -5.92 Mn |
| Oct 31, 2024 | -6.86 Mn |
| Jul 31, 2024 | -7.69 Mn |
| Apr 30, 2024 | -8.35 Mn |
| Jan 31, 2024 | -9.33 Mn |
| Oct 31, 2023 | -5.51 Mn |
| Jul 31, 2023 | -3.93 Mn |
| Jan 31, 2023 | -3.35 Mn |
| Oct 31, 2022 | -147,392.83 |
| Jan 31, 2022 | -2.22 Mn |
| Oct 31, 2021 | -3.67 Mn |